

bioRxiv preprint doi: https://doi.org/10.1101/2024.09.16.613345; this version posted October 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.




Supplementary Information

SI Fig. 1 TIRTL-seq identifies expansions and contractions in the CD4+ T cell repertoire. Each dot represents TCR β clonotype, frequency at two timepoints is plotted in log-scale. Orange and green color show significantly expanding and contracting clones respectively.



SI Fig. 2 a. Gating strategy and representative flow plots for *in vitro* validation experiments. **b.** *In vitro* validation of predicted TCR specificity. Bars show average percentage of GFP+ cells out of TCR-transgenic Jurkat cells (mCherry+), dots show replicates.



SI Fig. 3 Anti-EBV VCA (left) and Anti-SARS-CoV-2 Spike IgG levels. Lowest dashed line shows seronegativity cut-offs.